Carbon-ion radiotherapy for octogenarians with locally advanced non-small-cell lung cancer

Author:

Hayashi Kazuhiko,Yamamoto Naoyoshi,Nakajima Mio,Nomoto Akihiro,Ishikawa Hitoshi,Ogawa Kazuhiko,Tsuji Hiroshi

Abstract

Abstract Purpose The clinical significance of carbon-ion radiotherapy (CIRT) for octogenarians with locally advanced non-small-cell lung cancer (LA-NSCLC) remains unclear. We aimed to evaluate the clinical outcomes of CIRT alone for octogenarians with LA-NSCLC. Materials and methods We evaluated 32 patients who underwent CIRT alone between 1997 and 2015. The median age was 82.0 years (range, 80–88 years). In terms of clinical stage (UICC 7th edition), 7 (21.9%), 10 (31.3%), 11 (34.4%), and 4 (12.5%) patients had stage IIA, IIB, IIIA, and ΙΙΙB disease, respectively. The median CIRT dose was 72.0 Gy (relative biological effectiveness), and the median follow-up period was 33.1 months. Results All patients successfully completed CIRT. Regarding grade ≥ 2 toxicities, 1 (3.1%), 3 (9.4%), and 4 (0.7%) patients developed grade 3 radiation pneumonitis, grade 2 radiation pneumonitis, and grade 2 dermatitis, respectively. No grade ≥ 4 toxicities were observed. The 2 year LC, PFS, and OS rates were 83.5%, 46.7%, and 68.0%, respectively. Conclusion CIRT alone is safe and effective for octogenarians with LA-NSCLC.

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging

Reference22 articles.

1. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7:220–33.

2. Statistics of Japan. http://www.e-stat.go.jp/en. Published 2017.

3. Cancer Information Service. http://gdb.ganjoho.jp/graph_db/gdb1?dataType=20&graphId=101&totalTarget=11&_useLog=on&_stackedRaito=on&_showErrorBar=on&_useUnknownStage=on&_smTypes=on&_smTypes=on&_smTypes=on&_smTypes=on&_smTypes=on&_smTypes=on&_smTypes=on&_smTypes=on&_smTypes=on&_smType. Published 2018.

4. Oh IJ, Ahn SJ. Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision. Radiat Oncol J. 2017;35:16–24.

5. Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, et al. The outcome of combined-modality therapy for stage III non–small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201–6.

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3